The clinical application of selective tau imaging biomarkers is expected to become more and more important as it provides important information regarding tau pathophysiology in AD and non-AD tauopathies, allowing correlation of brain tau load with cognitive function, monitoring disease progression and evaluation of therapeutic efficacy of newly developed drugs aimed at modulating tau pathology (146). The gene discussed is MAPT; the disease is Alzheimer disease.